You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
ASTROCYTE ACTIVATION BY SMALL MOLECULE P2Y1 AGONISTS FOR TREATMENT OF TBI
SBC: ASTROCYTE PHARMACEUTICALS INC. Topic: 105DESCRIPTION provided by applicant Traumatic brain injuries TBI are an area of significant unmet need with no approved therapeutics and a national burden of $ billion annually Astrocyte Pharmaceuticals is developing a small molecule pharmaceutical agent that would be administered by intravenous injection by emergency responders or a medical professional within hours of injury to limit n ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
GPCR antagonists as anti-Ebola virus entry inhibitors
SBC: MICROBIOTIX, INC. Topic: RDESCRIPTION provided by applicant Ebola EBOV and Marburg MARV viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as biosafety level agents Currently there is no effective vaccine or therapeutic treatment against f ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Novel filovirus entry inhibitors based on a pseudo-symmetrical biphenyl core
SBC: MICROBIOTIX, INC. Topic: RDESCRIPTION provided by applicant Ebola EBOV and Marburg MARV viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as biosafety level agents Currently there is no effective vaccine or therapeutic treatment against f ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Lipoprotein synthesis inhibitors for multi-drug resistant Gram-negative therapy
SBC: MICROBIOTIX, INC. Topic: NIAIDDESCRIPTION provided by applicant The increasing prevalence of drug resistant bacterial infections highlights the critical medical need for new agents that are not susceptible to existing resistance mechanisms Few new agents are in development for Gram negative bacteria which take up small molecules sparingly and efflux most compounds that reach the periplasm A particularly problematic group ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
A Structural Brain MRI Dementia Forecast Tool
SBC: CORTICOMETRICS LLC Topic: NIADESCRIPTION provided by applicant Alzheimerandapos s disease AD the most common type of dementia is a devastating disease with no available treatment or prevention The current lifetime risk for a year old individual is estimated to be around Given current projections over million individuals will be diagnosed with Alzheimerandapos s disease by As the development of the ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Improved Performance of Neonatal Vascular Access Catheters via 3D Magnetic Printing
SBC: N2 Biomedical, LLC Topic: NICHDDESCRIPTION provided by applicant Clinical treatment of infants in the neonatal intensive care unit NICU is particularly challenging due to their small anatomies medical instability and immature physiological processes Treatment is often complicated by the lack of therapeutic devices and instrumentation designed specifically to accommodate this unique patient population For instance curr ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Portable Multimode Persufflation/Perfusion System for Extended Hypothermic Kidney Preservation
SBC: GINER INC Topic: NIDDKDESCRIPTION provided by applicant Portable Multimode Persufflation Perfusion System for Extended Hypothermic Kidney Preservation In over patients in the US started treatment for end stage renal disease ESRD These patients spend on average $ annually on treatment including dialysis In The U S the current waiting list for organ transplantation holds over patient ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Development of PAR2 Pepducins for the Treatment of Atopic Dermatitis
SBC: OASIS PHARMACEUTICALS, LLC Topic: NIAMSDESCRIPTION provided by applicant Atopic dermatitis AD or severe eczema is a very common life long skin disease with of adults in the US requiring systemic therapy Clinical manifestations of AD include multiple inflamed lesions erosions accompanied by lichenification thick leathery skin fibrotic papules and severely dry skin with increased susceptibility to infection A major uncont ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Cloud quantitative imaging for whole-body tumor burden in neurofibromatoses
SBC: IQ MEDICAL IMAGING LLC Topic: 102DESCRIPTION provided by applicant The neurofibromatoses NFs including NF NF and schwannomatosis are a group of autosomal dominant neurogenetic disorders characterized by a predisposition in virtually of patients to develop multiple nerve sheath tumors The determination of tumor burden on magnetic resonance imaging MRI images is crucial for the management of NF patients which is ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Identification of patients with diabetes at high risk for treatment failure
SBC: LP INFORMATION TECHNOLOGY INC. Topic: 200DESCRIPTION provided by applicant The overall goal of this project is to improve quality of care of patients with diabetes by identifying patients who may have particular difficulty reaching treatment targets and who could therefore potentially benefit from additional resources Investigators propose to achieve this goal by developing a technology to accurately identify patients at high risk f ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health